From a $50 million commitment to support front line healthcare workers battling the pandemic to our investigational Janssen COVID-19 vaccine work, Johnson & Johnson was recognized for our efforts to help protect people and vulnerable communities globally in 2020. Read about these achievements. | Johnson & Johnson

JUST IN: A preclinical study published in Nature shows that Johnson & Johnson’s investigational vaccine has shown positive early data for eliciting an immune response against SARS-CoV-2, the virus that causes COVID-19. According to the World Health Organization, as of July 2020, global cases have now surpassed 16 million. Learn more about the study’s findings and how J&J is harnessing its science, scale and expertise to help fight the pandemic. | Johnson & Johnson